Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ABBV-744

Phase 1Small molecule

ABBV-744 is one of 45 small molecule programs targeting Myelofibrosis. It is currently in Phase 1.

1

Indications

2

Total Trials

1

Active Trials

44

Competitors

Pipeline

Status by Indication[3][1]

Indication

MyelofibrosisActive, not recruiting

MyelofibrosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

49 competitors in Myelofibrosis

#DrugCompanyPhaseTrials

Jakafi

Ojjaara

GGlaxo Dba Glaxosmithkline

Tepadina

Jazz Pharmaceuticals

Rifadin

Droxia

Sporanox

SSebela Pharmaceuticals Development LLC

Vonjo

Xpovio

KKaryopharm Therapeutics Inc

Navitoclax

Fludara

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Myelofibrosis

NCT04454658

Clinical

Trials by Indication[1]

Myelofibrosis1 trial

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Active, not recruiting· AbbVie logo

AbbVie·Phase 1·NCT04454658·21 enrolled

Acute Myeloid Leukemia1 trial

A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer

Terminated· AbbVie logo

AbbVie·Phase 1·NCT03360006·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ABBV-744. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABBV-744 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABBV-744. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AbbVie

Related News